Enjoy complimentary customisation on priority with our Enterprise License!
Psoriatic arthritis is an interminable joint pain that can affect the skin in wrist joint, outer joints of fingers and toes, lower back, knees, and ankles. It leads to inflammation in people with psoriasis, which can cause scaly red and white skin patches. Psoriatic arthritis can also affect the back and sacroiliac joints of the pelvis. Doctors are adopting nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), immunosuppressants, steroid injections, and joint replacement surgery to treat this disease. Technavio’s market research analysts have predicted that with the introduction of these treatments as some of the most promising approaches to treat psoriatic arthritis, the global psoriatic arthritis market will witness growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II drug development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the phase I and phase III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the pre-clinical stage.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of psoriatic arthritis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
The subcutaneous route of administration (ROA) involves the administration of drug directly into the layer of the skin below the dermis and the epidermis. It has been observed that the majority of total therapeutics are being developed for subcutaneous administration.
According to this pipeline analysis report, majority of the molecules that are currently in the drug development pipeline for psoriatic arthritis are being developed as monoclonal antibody. Monoclonal antibodies are made of identical immune cells that are clones of a parent cell.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.